Canaccord Genuity Reiterates Buy on Teva Pharmaceutical Industries Ltd (TEVA)

By admin | 6 years ago

Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA)‘s stock had its “buy” rating restated by equities researchers at Canaccord Genuity in a report issued on Friday.

Shares of Teva Pharmaceutical Industries Ltd traded down 0.21% during mid-day trading on Friday, hitting $38.61. Teva Pharmaceutical Industries Ltd has a 52 week low of $35.00 and a 52 week high of $51.15. The company has a market cap of $33.629 billion and a P/E ratio of 12.02.

Teva Pharmaceutical Industries Ltd last announced its earnings results on Wednesday, May 9th. The company reported $1.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.44 by $0.03. The company’s revenue for the quarter was up 25.0% on a year-over-year basis. On average, analysts predict that Teva Pharmaceutical Industries Ltd will post $1.31 earnings per share next quarter.

A number of other firms have also recently commented on TEVA. Analysts at UBS AG (NYSE: UBS) cut their price target on shares of Teva Pharmaceutical Industries Ltd from $60.00 to $52.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Separately, analysts at Citigroup (NYSE: C) cut their price target on shares of Teva Pharmaceutical Industries Ltd to $49.00 in a research note to investors on Friday. Finally, analysts at Needham & Company reiterated a “hold” rating on shares of Teva Pharmaceutical Industries Ltd in a research note to investors on Friday.

Teva Pharmaceutical Industries Limited (Teva) is a global pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories.

About the author